Suchergebnisse - "Kaiser, Martin"

PubPharm (14)

1

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

2

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy : results from a multicenter, phase II, randomized, controlled trial (MUKfive)

enthalten in: Haematologica | 2021

von Yong, K. | Hinsley, S. | Auner, H. | +16

CommentIn: Haematologica. 2021 Oct 01;106(10):2539-2541. - PMID 33910336

3

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

4

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

5

Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma : Results of the Phase 2 MUK four Trial

enthalten in: Clinical lymphoma, myeloma & leukemia | 2021

von Brown, S. | Pawlyn, C. | Tillotson, A. | +9

6

A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients

enthalten in: British journal of haematology | 2020

von Bird, S. | Pawlyn, C. | Nallamilli, S. | +6

7

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Jackson, G. | Davies, F. | Pawlyn, C. | +20

8

Health-related quality of life in the ENDEAVOR study : carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

enthalten in: Blood cancer journal | 2019

von Ludwig, H. | Moreau, P. | Dimopoulos, M. | +7

9

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

enthalten in: European journal of haematology | 2013

von Kaiser, M. | Heider, U. | Mieth, M. | +3

10

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib

enthalten in: Clinical lymphoma, myeloma & leukemia | 2010

von Heider, U. | Rademacher, J. | Kaiser, M. | +3